Shares of Imunon, Inc. (NASDAQ:IMNN – Get Free Report) rose 5.6% on Tuesday . The company traded as high as $1.15 and last traded at $1.14. Approximately 294,313 shares were traded during trading, a decline of 74% from the average daily volume of 1,151,619 shares. The stock had previously closed at $1.08.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Imunon in a report on Thursday, August 15th.
Check Out Our Latest Research Report on Imunon
Imunon Stock Performance
Imunon (NASDAQ:IMNN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04. Equities research analysts forecast that Imunon, Inc. will post -1.71 EPS for the current year.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
See Also
- Five stocks we like better than Imunon
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- 3 Tickers Leading a Meme Stock Revival
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.